US Stock MarketDetailed Quotes
PTGX Protagonist Therapeutics
- 43.800
- -1.150-2.56%
Close Nov 29 13:00 ET
- 43.800
- 0.0000.00%
Post 17:01 ET
2.61BMarket Cap15.99P/E (TTM)
45.258High43.590Low320.21KVolume44.590Open44.950Pre Close14.06MTurnover0.67%Turnover RatioLossP/E (Static)59.60MShares48.89052wk High4.91P/B2.08BFloat Cap18.07052wk Low--Dividend TTM47.51MShs Float50.540Historical High--Div YieldTTM3.71%Amplitude4.470Historical Low43.921Avg Price1Lot Size
Protagonist Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -4.70%-27.86M | 1,123.79%268.62M | 20.14%-27.43M | 35.05%-70.24M | 153.61%16.96M | -5.60%-26.61M | -92.43%-26.24M | 8.81%-34.35M | -0.25%-108.14M | -17.43%-31.64M |
| Net income from continuing operations | 2.62%-33.21M | 20.40%-30.62M | 714.80%207.34M | 38.02%-78.96M | 179.94%27.34M | -9.20%-34.11M | 6.28%-38.46M | -61.13%-33.73M | -1.47%-127.39M | 7.35%-34.19M |
| Depreciation and amortization | -21.77%647K | 8.65%892K | -1.44%820K | -1.69%3.31M | -0.95%832K | -3.05%827K | -2.61%821K | -0.12%832K | 21.41%3.37M | 2.56%840K |
| Other non cash items | ---- | ---- | ---- | --194K | --0 | --0 | --0 | --194K | ---- | ---- |
| Change In working capital | -389.32%-2.63M | 7,144.00%291.06M | -2,950.34%-243.33M | -151.24%-19.51M | -471.73%-16.46M | 232.94%908K | -79.56%4.02M | 66.57%-7.98M | -134.34%-7.77M | -179.62%-2.88M |
| -Change in receivables | 10.26%43K | 2,499,900.00%300M | -707,321.95%-290.04M | -335.50%-9.99M | -12,295.12%-10M | -98.52%39K | -99.95%12K | 99.83%-41K | 563.61%4.24M | -45.70%82K |
| -Change in prepaid assets | -84.90%-1.16M | -241.15%-2.01M | -216.26%-915K | -53.30%1.75M | -94.88%171K | -194.16%-629K | 192.83%1.42M | -38.47%787K | 216.33%3.75M | 661.51%3.34M |
| -Change in payables and accrued expense | 52.17%3.33M | -168.55%-2.24M | 140.76%3.28M | 25.82%-8.53M | -5.47%-5.94M | 166.05%2.19M | 231.21%3.26M | -11,398.57%-8.05M | -172.45%-11.5M | -204.65%-5.63M |
| -Change in other current liabilities | 76.05%-166K | 23.09%-523K | -3.26%-696K | -3.08%-2.74M | -3.11%-696K | -3.28%-693K | -2.87%-680K | -3.06%-674K | -22.63%-2.66M | 0.30%-675K |
| -Change in other working capital | ---4.68M | ---4.17M | --45.05M | ---- | ---- | ---- | ---- | ---- | 87.57%-1.6M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -4.70%-27.86M | 1,123.79%268.62M | 20.14%-27.43M | 35.05%-70.24M | 153.61%16.96M | -5.60%-26.61M | -92.43%-26.24M | 8.81%-34.35M | -0.25%-108.14M | -17.43%-31.64M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1,439.27%-208.71M | -442.05%-88.12M | -38.21%6.07M | -142.92%-39.26M | -1,657.48%-61.29M | -123.67%-13.56M | -25.83%25.76M | 319.53%9.83M | 676.72%91.47M | -85.88%3.94M |
| Net PPE purchase and sale | -91.83%-775K | 84.09%-28K | -2,320.00%-242K | 23.40%-609K | 72.86%-19K | -149.38%-404K | 39.31%-176K | 96.34%-10K | 27.79%-795K | 64.29%-70K |
| Net investment purchase and sale | -1,480.65%-207.94M | -439.62%-88.09M | -35.82%6.31M | -141.89%-38.65M | -1,629.79%-61.27M | -122.90%-13.16M | -25.94%25.94M | 334.02%9.84M | 725.13%92.26M | -85.73%4.01M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1,439.27%-208.71M | -442.05%-88.12M | -38.21%6.07M | -142.92%-39.26M | -1,657.48%-61.29M | -123.67%-13.56M | -25.83%25.76M | 319.53%9.83M | 676.72%91.47M | -85.88%3.94M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -65.88%12.05M | -97.62%2.57M | -72.80%7.2M | 804.96%170.48M | -4.70%527K | 5,093.38%35.32M | 15,807.65%108.17M | 56.35%26.46M | -85.50%18.84M | -74.55%553K |
| Net common stock issuance | --0 | --0 | --0 | 807.72%132.1M | --8K | ---78K | --107.87M | 66.99%24.3M | -88.25%14.55M | --0 |
| Proceeds from stock option exercised by employees | -65.95%12.05M | 164.34%2.57M | 244.94%7.8M | 780.08%39.15M | -6.15%519K | 5,089.59%35.39M | 48.55%973K | -11.61%2.26M | -29.21%4.45M | -76.36%553K |
| Net other financing activities | --0 | --0 | -500.00%-600K | -371.78%-769K | --0 | --0 | -2,776.00%-669K | 46.24%-100K | 13.76%-163K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -65.88%12.05M | -97.62%2.57M | -72.80%7.2M | 804.96%170.48M | -4.70%527K | 5,093.38%35.32M | 15,807.65%108.17M | 56.35%26.46M | -85.50%18.84M | -74.55%553K |
| Net cash flow | ||||||||||
| Beginning cash position | 51.04%355.87M | 35.09%172.79M | 48.41%186.95M | 1.68%125.97M | 50.78%230.75M | 95.59%235.61M | 29.59%127.91M | 1.68%125.97M | 5.15%123.89M | 26.72%153.04M |
| Current changes in cash | -4,524.55%-224.52M | 69.99%183.08M | -829.09%-14.16M | 2,711.57%60.98M | -61.34%-43.8M | -114.82%-4.86M | 394.49%107.7M | 107.70%1.94M | -65.00%2.17M | -975.43%-27.15M |
| Effect of exchange rate changes | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 28.57%-90K | 240.91%75K |
| End cash Position | -43.08%131.35M | 51.04%355.87M | 35.09%172.79M | 48.41%186.95M | 48.41%186.95M | 50.78%230.75M | 95.59%235.61M | 29.59%127.91M | 1.68%125.97M | 1.68%125.97M |
| Free cash flow | -6.01%-28.64M | 1,116.86%268.59M | 19.46%-27.67M | 34.96%-70.85M | 153.43%16.94M | -6.51%-27.02M | -89.69%-26.41M | 9.44%-34.36M | 0.03%-108.93M | -16.84%-31.71M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data